Inotiv (NASDAQ:NOTV) PT Lowered to $10.00 at Craig Hallum

Inotiv (NASDAQ:NOTVFree Report) had its price target cut by Craig Hallum from $25.00 to $10.00 in a research note released on Thursday morning, Benzinga reports. They currently have a buy rating on the stock.

Separately, Jefferies Financial Group cut Inotiv from a buy rating to a hold rating and reduced their price target for the stock from $11.50 to $3.75 in a research report on Tuesday, May 14th.

Read Our Latest Report on NOTV

Inotiv Price Performance

Shares of NASDAQ:NOTV opened at $1.93 on Thursday. Inotiv has a fifty-two week low of $1.61 and a fifty-two week high of $11.42. The business has a 50-day moving average of $6.47 and a two-hundred day moving average of $4.78. The stock has a market capitalization of $50.12 million, a P/E ratio of -0.70 and a beta of 3.37.

Institutional Trading of Inotiv

Several hedge funds have recently added to or reduced their stakes in NOTV. Algert Global LLC bought a new position in Inotiv in the 3rd quarter worth approximately $46,000. Corton Capital Inc. acquired a new stake in shares of Inotiv in the third quarter worth $58,000. Vanguard Personalized Indexing Management LLC bought a new position in Inotiv during the fourth quarter worth $77,000. Lazard Asset Management LLC acquired a new position in Inotiv during the 1st quarter valued at $266,000. Finally, Denali Advisors LLC bought a new stake in Inotiv in the 1st quarter valued at $277,000. Institutional investors own 18.17% of the company’s stock.

About Inotiv

(Get Free Report)

Inotiv, Inc provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.

Further Reading

Receive News & Ratings for Inotiv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inotiv and related companies with's FREE daily email newsletter.